Novolog Injection, Solution
NDC Package 0169-7501-90
Package Information
Novolog (insulin aspart) injection is insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk, this product is identified by NDC 0169-7501 and is authorized under FDA application BLA020986.
Identification & Billing
- RxCUI: 1653196 - insulin aspart 100 UNT/ML in 3 ML Cartridge
- RxCUI: 1653196 - 3 ML insulin aspart, human 100 UNT/ML Cartridge
- RxCUI: 1653196 - insulin, aspart, human 100 UNT/ML per 3 ML Cartridge
- RxCUI: 1653198 - NovoLOG 100 UNT/ML in 3 ML Cartridge
- RxCUI: 1653198 - 3 ML insulin aspart, human 100 UNT/ML Cartridge [NovoLog]
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Regulatory & Marketing
Hierarchy Structure
- 0169 - Novo Nordisk
- 0169-7501 - Novolog
- 0169-7501-90 - 1 VIAL, GLASS in 1 CARTON / 10 mL in 1 VIAL, GLASS
- 0169-7501 - Novolog
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0169-7501). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0169-7501-90 identifies a specific commercial package of 1 vial, glass in 1 carton / 10 ml in 1 vial, glass of Novolog, a human prescription drug labeled by Novo Nordisk. This injection, solution is formulated for intravenous; subcutaneous use and contains insulin aspart as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk on August 27, 2001. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.
How is this Novo Nordisk product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00169750190. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
